Deciphera DCC-3014-02-001: Vimseltinib in Adults With Active Chronic Graft Versus Host Disease

Deciphera DCC-3014-02-001: Vimseltinib in Adults With Active Chronic Graft Versus Host Disease

Es posible que algunos contenidos no estén disponibles en español.

Purpose of this Study

We are doing this study to find out if an investigational drug called vimseltinib (the study drug) is a safe and effective option for people with active Chronic Graft Versus Host Disease (cGVHD).

Who Can Participate?

Eligibility

Adults ages 18+ who:
  • Are diagnosed with moderate-to-severe cGVHD after receiving an allogeneic hematopoietic stem cell transplant
  • Have symptoms that became worse despite at least 2 previous lines of systemic therapy
For more information, contact the study team at jennifer.tichon@duke.edu.

Age Range

18-110

Sex/Genders

Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No

What is Involved?

Description

If you choose to join this study, you will take the study drug at an assigned dose level. Participants will get a random assignment to different dose levels, and the study doctor can let you know what your assigned dose level is.

Locations

Duke University Hospital

Visit Timing

Weekdays

Compensation

No

Spanish Materials Available

No

Study Details

Full Title

Deciphera DCC-3014-02-001: A Phase 2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, PK, and Efficacy of Vimseltinib in Adults With Active Chronic GVHD After Failure of Prior
Systemic Therapy

Principal Investigator

Mitchell
Horwitz

Protocol Number

PRO00116796

NCT ID

NCT06619561

Phase

II

Enrollment Status

Pending Open to Enrollment